Related references
Note: Only part of the references are listed.Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Ele Ferrannini et al.
DIABETES CARE (2013)
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Population Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Patients With Type 2 Diabetes
Matthew M. Riggs et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
Vivian A. Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
Leo Seman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Increased Mortality of Patients With Diabetes Reporting Severe Hypoglycemia
Rozalina G. McCoy et al.
DIABETES CARE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range
C. J. Bailey et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
Ishan Hirji et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2012)
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing et al.
DIABETES CARE (2011)
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
James F. List et al.
KIDNEY INTERNATIONAL (2011)
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
R. E. Aubert et al.
DIABETES OBESITY & METABOLISM (2010)
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
J. E. Gerich
DIABETIC MEDICINE (2010)
Pioglitazone: beyond glucose control
Pedro de Pablos-Velasco
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain
E. Marrett et al.
DIABETES OBESITY & METABOLISM (2009)
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management(RECAP-DM) Study
F. Alvarez Guisasola et al.
DIABETES OBESITY & METABOLISM (2008)
Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors
C Daousi et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women
EJ Boyko et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Intentional weight loss and mortality among overweight individuals with diabetes
DF Williamson et al.
DIABETES CARE (2000)
Share Paper
